Last reviewed · How we verify
STREPTOMYCIN SULFATE
Streptomycin sulfate is a marketed antibiotic with a key composition patent expiring in 2028. Its long-standing presence in the market provides a strong foundation and established usage patterns. The primary risk is the potential increase in generic competition following the 2028 patent expiry.
At a glance
| Generic name | STREPTOMYCIN SULFATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1946 |
Approved indications
Common side effects
Key clinical trials
- Ciprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin for Bubonic Plague (PHASE3)
- An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB) (PHASE2)
- Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old Infants (PHASE3)
- The Individualized M(X) Drug-resistant TB Treatment Strategy Study (PHASE4)
- The Effect of Intralesian Injection of Umbilical Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide on Type 1:3 Collagen Ratio and Interleukin-10 Levels in Keloid: A Randomised Controlled Trial (PHASE4)
- Comparison of Keloid Volume and Symptoms Reduction Between Intralesional Umbilical-Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide Injection as Keloid Therapy: A Randomised Controlled Trial (PHASE4)
- Induced Pluripotent Stem Cells for the Development of Novel Drug Therapies for Inborn Errors of Metabolism (iPSC-IEM)
- Mucosal-Associated Invariant T Cells in Cases of Miscarriage
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |